• 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2020-03
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • br Conclusion br In conclusion MpBC


    6. Conclusion
    In conclusion, MpBC is a rare entity among breast carcinomas in Poland, which is similar to the reports of MpBC from all over the world. It comprises of a heterogeneous and histologically diverse group of cancers consisting of epithelial and mesenchymal ele-ments. Most of MpBCs present with poor prognostic indicators and show lack of steroid hormone receptors Thapsigargin (ER, PR) as well as HER2. Due to the rarity of the disease, poorer prognosis and sub-optimal response to systemic therapies further research is needed for formulating comprehensive treatment plans. Also more data on the biologic characteristic of MpBC may allow us to understand the reason why it presents differently from other invasive breast cancer types in the term of clinicopathology.
    [6] Weigelt B, Geyerb FC, Reis-Filhob JS. Histological types of breast cancer: how special are they? Mol Oncol 2010;4:192e208. [7] Jung SY, Kim HY, Nam BH, et al. Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. Breast Canc Res Treat 2010;120:627e37. [8] Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology e college of American pathologists (ASCO/CAP) clinical practice guideline update. J Clin Oncol 2013;31(31):3997e4013.
    [9] Pezzi CM, Patel-Parekh L, Cole K, Franko J, Klimberg VS, Bland K. Character-istics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol 2007;14:166e73.  [10] Song Y, Liu X, Zhang G, et al. Unique clinicopathological features of meta-plastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators. World J Surg Oncol 2013;11:129. [11] Rakha EA, Coimbra NDM, Hodi Z, Juneinah E, Ellis IO, Lee AHS. Immunoprofile of metaplastic carcinomas of the breast. Histopathology 2017;70:975e85. [12] Gunhan-Bilgen I, Memis A, Ustun EE, Zekioglu O, Ozdemir N. Metaplastic carcinoma of the breast: clinical, mammographic and sonographic findings with histopathologic correlation. AJR Am J Roentgenol 2002;178:1421e5. [13] Shin HJ, Kim HH, Kim SM, et al. Imaging features of metaplastic carcinoma with chondroid differentiation of the breast. AJR Am J Roentgenol 2007;188: 691e6.
    [18] Esbah O, Turkoz FP, Turker I, et al. Metaplastic breast carcinoma: case series and review of the literature. Asian Pac J Cancer Prev 2012;13:4645e9. [19] Schwartz TL, Mogal H, Papageorgiou C, Veerapong J, Hsueh EC. Metaplastic breast cancer: histologic characteristics, prognostic factors and systemic treatment strategies. Exp Hematol Oncol 2013;2:31e40.
    [22] Luini A, Aguilar M, Gatti G, et al. Metaplasic carcinoma of the breast, an un-usual disease with worse prognosis: the experience of the European Institute on Oncology and review of the literature. Breast Canc Res Treat 2007;101: 349e53. r> [23] Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, et al. Characterization of a naturally occurring breast cancer subtype enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 2009;69: 4116e24.
    [24] Weigelt B, Kreike B, Reis-Filho JS. Metaplastic breast carcinoma are basal like breast cancers: a genomic profiling analysis. Breast Canc Res Treat 2009;117: 273e80.
    [25] Zhang Y, Toy KA, Kleer CG. Metaplastic breast carcinomas are enriched in markers of tumor-initiating cells and epithelial to mesenchymal transition. Mod Pathol 2012;25:178e84.
    [26] Leibl S, Gogg-Kammerer M, Sommersacher A, Denk H, Moinfar F. Metaplastic breast carcinomas: are they of myoepithelial differentiation?: immunohisto-chemical profile of the sarcomatoid subtype using novel myoepithelial markers. Am J Surg Pathol 2005;26(7):347e53.